Arcede Pharma is in full swing with the preparations for clinical studies with drug candidate RCD405. CEO Mia Lundblad has announced that she will leave her position for a more research-oriented role outside the company. Lundblad will continue as CEO until the beginning of February, when the company's CFO Erik Magnusson will take over as acting CEO. 

Read the full article at biostock.se:

https://www.biostock.se/en/2023/12/arcede-pharma-appoints-acting-ceo/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/arcede-pharma/r/biostock--arcede-pharma-appoints-acting-ceo,c3897609

(c) 2023 Cision. All rights reserved., source Press Releases - English